Gilead Sciences (NASDAQ:GILD) Given New $95.00 Price Target at Barclays
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective raised by Barclays from $84.00 to $95.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Sanford C. Bernstein started coverage on […]
More Stories
Tullow Oil (LON:TLW) Stock Price Down 7.6% After Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report) fell 7.6% during mid-day trading on Monday after Shore Capital lowered their...
Tullow Oil (LON:TLW) Stock Price Down 7.6% on Analyst Downgrade
Tullow Oil plc (LON:TLW – Get Free Report)’s stock price dropped 7.6% during trading on Monday after Shore Capital lowered...
Tullow Oil (LON:TLW) Shares Down 7.6% on Analyst Downgrade
Shares of Tullow Oil plc (LON:TLW – Get Free Report) traded down 7.6% on Monday after Shore Capital lowered their...
Head-To-Head Contrast: Avient (NYSE:AVNT) & ASP Isotopes (NASDAQ:ASPI)
Avient (NYSE:AVNT – Get Free Report) and ASP Isotopes (NASDAQ:ASPI – Get Free Report) are both basic materials companies, but...
Innoviva (NASDAQ:INVA) versus Roche (OTCMKTS:RHHBY) Head to Head Review
Innoviva (NASDAQ:INVA – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is...
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Chardan Capital
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective decreased by equities research analysts at Chardan Capital from...